Dimerix (ASX:DXB) has confirmed that the first clinical trial site in Japan is now open for recruitment, triggering the first development milestone payment of ¥400 million (~AU$4.3 million) from FUSO Pharmaceutical Industries, the exclusive licensee of DMX-200 for FSGS in Japan. …
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 Australian Biotech
Latest Video
New Stories
-
Dimerix says first ACTION3 trial site activated in Japan and first milestone payment triggered
May 30, 2025 - - Australian Biotech -
Arrotex Pharmaceuticals appointed exclusive partner for Juniper Biologics
May 29, 2025 - - Latest News -
TGA approves new therapy for children with growth hormone deficiency
May 29, 2025 - - Latest News -
AbbVie Australia appoints Dr Carly Levetan associate medical director
May 29, 2025 - - Latest News -
For patients, it's about understanding their experience and accessing the touchpoints
May 29, 2025 - - Latest News -
Priceline Pharmacy launches annual event with national menopause project
May 28, 2025 - - Latest News -
Anne Ruston welcomes her reappointment to health and the addition of NDIS
May 28, 2025 - - Latest News